Table 4 Baseline characteristics, occurrence of MACE between patients with PDC ≥ 0.5 and PDC < 0.5 in secondary prevention subgroup
Secondary prevention N = 65,283 | |||
|---|---|---|---|
Patients with PDC ≥ 0.5 N = 3515 | Patients with PDC < 0.5 N = 61,768 | P value | |
Baseline characteristics | |||
Demographic characteristics | |||
Mean age, mean (SD) | 60.5 (10.5) | 59.0 (11.3) | < 0.001a |
Female, n (%) | 1494 (42.5) | 33,504 (54.2) | < 0.001b |
CCI, mean (SD) | 1.5 (1.4) | 1.2 (1.2) | < 0.001b |
Comorbidities, n (%) | |||
Hypertension | 2866 (81.5) | 50,698 (82.1) | 0.416b |
Dyslipidemia | 1611 (45.8) | 28,043 (45.4) | 0.617b |
Diabetes mellitus | 1622 (46.1) | 25,066 (40.6) | < 0.001b |
Chronic kidney disease | 322 (9.2) | 5181 (8.4) | 0.109b |
All-cause resource utilization and cost | |||
Total direct medical cost (CNY), mean (SD) | 14,627.6 (21,026.1) | 8351.5 (12,308.9) | < 0.001a |
Number of outpatient visits, mean (SD) | 39.9 (43.8) | 31.7 (30.5) | < 0.001a |
Patients had hospitalization record, n (%) | 814 (23.2) | 8233 (13.3) | < 0.001b |
MACE in the 13th–24th months | |||
Patients with MACE, n (%) | 161 (4.6) | 1718 (2.8) | < 0.001b |
Mean number of MACE in patients with MACE, mean (SD) | 1.2 (0.4) | 1.3 (0.7) | 0.095a |
Days to the first MACE since index, mean (SD) | 552.8 (112.4) | 549.3 (107.3) | 0.694a |